Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer

Zoe E Betteridge, Lynsey Priest, Robert G Cooper, Neil J McHugh, Fiona Blackhall, Janine A Lamb

Research output: Contribution to journalArticle

15 Downloads (Pure)

Abstract

BACKGROUND: The close temporal association between onset of some connective tissue diseases and cancer suggests a paraneoplastic association. Adult patients with scleroderma with anti-RNA polymerase III autoantibodies and adult patients with dermatomyositis with anti-transcriptional intermediary factor 1 (anti-TIF1) or anti-nuclear matrix protein 2 (anti-NXP2) autoantibodies have a significantly increased risk of developing cancer. Autoantibodies may serve as biomarkers for early detection of cancer and also could be relevant for prediction of responses to immune therapies. We aimed to test whether myositis and scleroderma specific or associated autoantibodies are detectable in individuals with lung cancer.

METHODS: Serum from 60 Caucasian patients with lung cancer (30 with small cell lung cancer, 30 with non-small cell lung cancer) was screened for myositis and scleroderma specific and associated autoantibodies by radiolabelled immunoprecipitation.

RESULTS: Anti-TIF1, anti-NXP2 or anti-RNA polymerase III autoantibodies were not detected in any of the 60 patients with lung cancer. Anti-glycyl-transfer RNA (tRNA) synthetase (anti-EJ) autoantibodies were detected in one patient with non-small cell lung cancer. No other known myositis or scleroderma autoantibodies were identified.

CONCLUSIONS: Myositis and scleroderma specific autoantibodies, including anti-TIF1, anti-NXP2 and anti-RNA polymerase III, are rare in patients with lung cancer without an autoimmune disease. We report here the first case of anti-EJ autoantibodies being detected in a patient with lung cancer without clinical or radiographic evidence of the anti-synthetase syndrome.

Original languageEnglish
Article number176
JournalArthritis Research & Therapy
Volume20
Issue number1
DOIs
Publication statusPublished - 9 Aug 2018

Fingerprint

Myositis
Autoantibodies
Lung Neoplasms
RNA Polymerase III
Non-Small Cell Lung Carcinoma
Amino Acyl-tRNA Synthetases
Connective Tissue Diseases
Dermatomyositis
Small Cell Lung Carcinoma
Ligases
Early Detection of Cancer
Immunoprecipitation
Autoimmune Diseases
Neoplasms
Biomarkers

Cite this

Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. / Betteridge, Zoe E; Priest, Lynsey; Cooper, Robert G; McHugh, Neil J; Blackhall, Fiona; Lamb, Janine A.

In: Arthritis Research & Therapy, Vol. 20, No. 1, 176, 09.08.2018.

Research output: Contribution to journalArticle

Betteridge, Zoe E ; Priest, Lynsey ; Cooper, Robert G ; McHugh, Neil J ; Blackhall, Fiona ; Lamb, Janine A. / Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. In: Arthritis Research & Therapy. 2018 ; Vol. 20, No. 1.
@article{38f9f9e280a24252a661a8d0cfa8f156,
title = "Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer",
abstract = "BACKGROUND: The close temporal association between onset of some connective tissue diseases and cancer suggests a paraneoplastic association. Adult patients with scleroderma with anti-RNA polymerase III autoantibodies and adult patients with dermatomyositis with anti-transcriptional intermediary factor 1 (anti-TIF1) or anti-nuclear matrix protein 2 (anti-NXP2) autoantibodies have a significantly increased risk of developing cancer. Autoantibodies may serve as biomarkers for early detection of cancer and also could be relevant for prediction of responses to immune therapies. We aimed to test whether myositis and scleroderma specific or associated autoantibodies are detectable in individuals with lung cancer.METHODS: Serum from 60 Caucasian patients with lung cancer (30 with small cell lung cancer, 30 with non-small cell lung cancer) was screened for myositis and scleroderma specific and associated autoantibodies by radiolabelled immunoprecipitation.RESULTS: Anti-TIF1, anti-NXP2 or anti-RNA polymerase III autoantibodies were not detected in any of the 60 patients with lung cancer. Anti-glycyl-transfer RNA (tRNA) synthetase (anti-EJ) autoantibodies were detected in one patient with non-small cell lung cancer. No other known myositis or scleroderma autoantibodies were identified.CONCLUSIONS: Myositis and scleroderma specific autoantibodies, including anti-TIF1, anti-NXP2 and anti-RNA polymerase III, are rare in patients with lung cancer without an autoimmune disease. We report here the first case of anti-EJ autoantibodies being detected in a patient with lung cancer without clinical or radiographic evidence of the anti-synthetase syndrome.",
author = "Betteridge, {Zoe E} and Lynsey Priest and Cooper, {Robert G} and McHugh, {Neil J} and Fiona Blackhall and Lamb, {Janine A}",
year = "2018",
month = "8",
day = "9",
doi = "10.1186/s13075-018-1678-9",
language = "English",
volume = "20",
journal = "Arthritis Research & Therapy",
issn = "1478-6362",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer

AU - Betteridge, Zoe E

AU - Priest, Lynsey

AU - Cooper, Robert G

AU - McHugh, Neil J

AU - Blackhall, Fiona

AU - Lamb, Janine A

PY - 2018/8/9

Y1 - 2018/8/9

N2 - BACKGROUND: The close temporal association between onset of some connective tissue diseases and cancer suggests a paraneoplastic association. Adult patients with scleroderma with anti-RNA polymerase III autoantibodies and adult patients with dermatomyositis with anti-transcriptional intermediary factor 1 (anti-TIF1) or anti-nuclear matrix protein 2 (anti-NXP2) autoantibodies have a significantly increased risk of developing cancer. Autoantibodies may serve as biomarkers for early detection of cancer and also could be relevant for prediction of responses to immune therapies. We aimed to test whether myositis and scleroderma specific or associated autoantibodies are detectable in individuals with lung cancer.METHODS: Serum from 60 Caucasian patients with lung cancer (30 with small cell lung cancer, 30 with non-small cell lung cancer) was screened for myositis and scleroderma specific and associated autoantibodies by radiolabelled immunoprecipitation.RESULTS: Anti-TIF1, anti-NXP2 or anti-RNA polymerase III autoantibodies were not detected in any of the 60 patients with lung cancer. Anti-glycyl-transfer RNA (tRNA) synthetase (anti-EJ) autoantibodies were detected in one patient with non-small cell lung cancer. No other known myositis or scleroderma autoantibodies were identified.CONCLUSIONS: Myositis and scleroderma specific autoantibodies, including anti-TIF1, anti-NXP2 and anti-RNA polymerase III, are rare in patients with lung cancer without an autoimmune disease. We report here the first case of anti-EJ autoantibodies being detected in a patient with lung cancer without clinical or radiographic evidence of the anti-synthetase syndrome.

AB - BACKGROUND: The close temporal association between onset of some connective tissue diseases and cancer suggests a paraneoplastic association. Adult patients with scleroderma with anti-RNA polymerase III autoantibodies and adult patients with dermatomyositis with anti-transcriptional intermediary factor 1 (anti-TIF1) or anti-nuclear matrix protein 2 (anti-NXP2) autoantibodies have a significantly increased risk of developing cancer. Autoantibodies may serve as biomarkers for early detection of cancer and also could be relevant for prediction of responses to immune therapies. We aimed to test whether myositis and scleroderma specific or associated autoantibodies are detectable in individuals with lung cancer.METHODS: Serum from 60 Caucasian patients with lung cancer (30 with small cell lung cancer, 30 with non-small cell lung cancer) was screened for myositis and scleroderma specific and associated autoantibodies by radiolabelled immunoprecipitation.RESULTS: Anti-TIF1, anti-NXP2 or anti-RNA polymerase III autoantibodies were not detected in any of the 60 patients with lung cancer. Anti-glycyl-transfer RNA (tRNA) synthetase (anti-EJ) autoantibodies were detected in one patient with non-small cell lung cancer. No other known myositis or scleroderma autoantibodies were identified.CONCLUSIONS: Myositis and scleroderma specific autoantibodies, including anti-TIF1, anti-NXP2 and anti-RNA polymerase III, are rare in patients with lung cancer without an autoimmune disease. We report here the first case of anti-EJ autoantibodies being detected in a patient with lung cancer without clinical or radiographic evidence of the anti-synthetase syndrome.

U2 - 10.1186/s13075-018-1678-9

DO - 10.1186/s13075-018-1678-9

M3 - Article

VL - 20

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

SN - 1478-6362

IS - 1

M1 - 176

ER -